Docoh
Loading...

TGTX TG Therapeutics

APP
Utility
Combination of ANTI-CD20 Antibody, P13 Kinase-delta Selective Inhibitor, and BTK Inhibitor to Treat B-cell Proliferative Disorders
10 Jun 21
Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor.
Michael S. WEISS, Hari P. MISKIN, Peter SPORTELLI
Filed: 12 Feb 21
GRANT
Utility
Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
6 Apr 21
Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor.
Michael S. Weiss, Hari P. Miskin, Peter Sportelli
Filed: 26 May 17
APP
Utility
Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor
14 Oct 20
Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorders.
Michael S. Weiss, Hari P. Miskin, Peter Sportelli, Swaroop K.V.S. Vakkalanka
Filed: 28 Jun 20
GRANT
Utility
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
3 Aug 20
Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorderes.
Michael S. Weiss, Hari P. Miskin, Peter Sportelli, Swaroop K. V. S. Vakkalanka
Filed: 27 Jun 17
  • 1
Patents are sorted by USPTO publication date, most recent first